6 results on '"Qu, Chang-Fa"'
Search Results
2. Impact of IGF-1, IGF-1R, and IGFBP-3 promoter methylation on the risk and prognosis of esophageal carcinoma.
- Author
-
Ye, Peng, Qu, Chang-Fa, and Hu, Xue-Lin
- Abstract
The aim of this study is to investigate IGF-1, IGF-1R, and IGFBP-3 methylations in esophageal carcinoma (EC) patients and their relationship with the development and prognosis of EC. This study population consisted of 264 patients (case group) whom EC radical resection was performed and 283 healthy individuals (control group). Methylation-specific PCR (MSP) detected the methylation status of IGF-1, IGF-1R, and IGFBP-3 in the peripheral blood in both groups. The expressions of IGF-1, IGF-1R, and IGFBP-3 in EC and adjacent normal tissues were detected by immunohistochemistry (IHC). The methylation rates of IGF-1, IGF-1R, IGFBP3, and IGF-1 + IGF1R + IGFBP3 in the case group were higher than those in the control group (all P < 0.05). Additionally, there were statistical significances for the methylation rates of IGF-1, IGF-1R, IGFBP3, and IGF-1 + IGF1R + IGFBP3 IGF-1 among patients of different clinicopathological features (all P < 0.05). The positive expression rates of IGF-1 and IGF-1R in EC were significantly higher than those in adjacent normal tissues (both P < 0.001), and the rate of IGFBP-3 in EC was significantly lower than that in adjacent normal tissues ( P < 0.05). Correlation analysis showed that IGF-1 and IGF1R gene promoter methylation was positively correlated with the positive expressions of IGF-1 ( r = 0.139, P = 0.024) and IGF-1R ( r = 0.135, P = 0.028), while the IGFBP3 methylation was negatively correlated with the positive expression of IGFBP3 ( r = −0.133, P = 0.031). The positive expressions of IGF-1, IGF-1R, and IGFBP-3 were related to different clinicopathological features (all P < 0.05). Cox multivariate analysis results showed that methylation status of IGF-1, IGF-1R, and IGF-1 + IGF1R + IGFBP3 ; expressions of IGF-1 and IGF-1R protein ; infiltration depth ; and lymph node metastasis (LNM) were independent factors of EC prognosis. Our study demonstrated that methylation of IGF-1, IGF1R, IGFBP3, and IGF-1 + IGF1R + IGFBP3 was closely linked with the occurrence of EC and patients' clinicopathological features. Besides, the methylation status of the target genes and the expressions of IGF-1 and IGF-1R protein were independent factors of EC prognosis, which could provide a direction for the prognosis and treatment of EC. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
3. Targeted alpha therapy for cancer.
- Author
-
Allen, Barry J., Raja, Chand, Rizvi, Syed, Li, Yong, Tsui, Wendy, Zhang, David, Song, Emma, Qu, Chang Fa, Kearsley, John, Graham, Peter, and Thompson, John
- Published
- 2004
- Full Text
- View/download PDF
4. Impact of IGF-1, IGF-1R, and IGFBP-3 promoter methylation on the risk and prognosis of esophageal carcinoma.
- Author
-
Ye P, Qu CF, and Hu XL
- Subjects
- Aged, Case-Control Studies, Esophageal Neoplasms pathology, Female, Follow-Up Studies, Gene Expression, Genetic Association Studies, Humans, Insulin-Like Growth Factor Binding Protein 3 metabolism, Insulin-Like Growth Factor I metabolism, Male, Middle Aged, Neoplasm Grading, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Proportional Hazards Models, Receptor, IGF Type 1 metabolism, Risk, Risk Factors, DNA Methylation, Esophageal Neoplasms genetics, Esophageal Neoplasms mortality, Insulin-Like Growth Factor Binding Protein 3 genetics, Insulin-Like Growth Factor I genetics, Promoter Regions, Genetic, Receptor, IGF Type 1 genetics
- Abstract
The aim of this study is to investigate IGF-1, IGF-1R, and IGFBP-3 methylations in esophageal carcinoma (EC) patients and their relationship with the development and prognosis of EC. This study population consisted of 264 patients (case group) whom EC radical resection was performed and 283 healthy individuals (control group). Methylation-specific PCR (MSP) detected the methylation status of IGF-1, IGF-1R, and IGFBP-3 in the peripheral blood in both groups. The expressions of IGF-1, IGF-1R, and IGFBP-3 in EC and adjacent normal tissues were detected by immunohistochemistry (IHC). The methylation rates of IGF-1, IGF-1R, IGFBP3, and IGF-1 + IGF1R + IGFBP3 in the case group were higher than those in the control group (all P < 0.05). Additionally, there were statistical significances for the methylation rates of IGF-1, IGF-1R, IGFBP3, and IGF-1 + IGF1R + IGFBP3 IGF-1 among patients of different clinicopathological features (all P < 0.05). The positive expression rates of IGF-1 and IGF-1R in EC were significantly higher than those in adjacent normal tissues (both P < 0.001), and the rate of IGFBP-3 in EC was significantly lower than that in adjacent normal tissues (P < 0.05). Correlation analysis showed that IGF-1 and IGF1R gene promoter methylation was positively correlated with the positive expressions of IGF-1 (r = 0.139, P = 0.024) and IGF-1R (r = 0.135, P = 0.028), while the IGFBP3 methylation was negatively correlated with the positive expression of IGFBP3 (r = -0.133, P = 0.031). The positive expressions of IGF-1, IGF-1R, and IGFBP-3 were related to different clinicopathological features (all P < 0.05). Cox multivariate analysis results showed that methylation status of IGF-1, IGF-1R, and IGF-1 + IGF1R + IGFBP3 ; expressions of IGF-1 and IGF-1R protein; infiltration depth; and lymph node metastasis (LNM) were independent factors of EC prognosis. Our study demonstrated that methylation of IGF-1, IGF1R, IGFBP3, and IGF-1 + IGF1R + IGFBP3 was closely linked with the occurrence of EC and patients' clinicopathological features. Besides, the methylation status of the target genes and the expressions of IGF-1 and IGF-1R protein were independent factors of EC prognosis, which could provide a direction for the prognosis and treatment of EC.
- Published
- 2016
- Full Text
- View/download PDF
5. Preclinical studies of bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model.
- Author
-
Abbas Rizvi SM, Li Y, Song EY, Qu CF, Raja C, Morgenstern A, Apostolidis C, and Allen BJ
- Subjects
- Animals, Chelating Agents pharmacology, Cycloheximide pharmacology, Humans, Male, Mice, Mice, Nude, Neoplasm Metastasis, Neoplasm Transplantation, Pentetic Acid pharmacology, Plasminogen Activator Inhibitor 2 chemistry, Rabbits, Serine Proteinase Inhibitors pharmacology, Bismuth pharmacology, Plasminogen Activator Inhibitor 2 metabolism, Prostatic Neoplasms therapy, Radioisotopes pharmacology
- Abstract
Objectives: The key objective of the study was to determine the single and multiple dose toxicity and efficacy of Bismuth-213 labeled PAI2 based targeted alpha therapy by selectively targeting uPA and uPAR in regressing prostate cancer in a nude mouse model. Targeted alpha therapy (TAT) is an experimental therapeutic modality for cancer. Another objective was to compare the in vivo pharmacokinetics using two different chelators to form the radioisotope-protein construct., Methods: The single and multiple intra-peritoneal (IP) dose toxicity and efficacy of 213BiPAI2 was investigated in nude mice and its toxicity in rabbits. CD 31 staining for vasculature and uPA expression were measured at different stages of tumor growth. The pharmacokinetics of the chelators cDTPA and CHX-A'' were measured., Results: All TAT regimes were well tolerated in mice and rabbits on biochemical and haematological examination. Capillaries became evident at six days post-cell inoculation. uPA expression was positive at all stages of tumour growth. No significant differences were observed between cDTPA and CHX-A. '' Inhibition of tumour growth was observed at 947 and 1421 MBq/kg single dose injection at three days post-PC3 cell inoculation. The three day post-inoculation multiple dose regime gave complete tumour growth inhibition at a total dose of 947 MBq/kg given on five successive days. Mice treated at 6, 12 and 18 days post-inoculation showed significantly slower tumour growth compared to controls., Conclusions: The efficacy of single and multiple dose TAT in mice was demonstrated within tolerance limits, the multiple dose regime being no more toxic than the single dose. Either of the two chelators could be used for 213Bi studies.
- Published
- 2006
- Full Text
- View/download PDF
6. In vivo studies of pharmacokinetics and efficacy of Bismuth-213 labeled antimelanoma monoclonal antibody 9.2.27.
- Author
-
Rizvi SM, Qu CF, Song YJ, Raja C, and Allen BJ
- Subjects
- Animals, Half-Life, Mice, Mice, Inbred BALB C, Mice, Nude, Tissue Distribution, Antibodies, Monoclonal pharmacokinetics, Antigens immunology, Antigens, Neoplasm immunology, Bismuth pharmacokinetics, Melanoma immunology, Proteoglycans immunology, Radioisotopes
- Abstract
Objectives: Key objectives of the study were to determine the pharmacokinetics and efficacy of the alpha emitting Bismuth-213 labeled 9.2.27 alpha-immunoconjugate (AIC)., Methods: Balb/c nude mice were injected with varying doses of AIC to determine the pharmacokinetics of the AIC. The results were normalized to percent counts per minute (CPM) per gram per 3.7 MBq of the AIC (%CPM/g/3.7MBq) for each organ. Efficacy was determined by injected varying doses of AIC to different stages of tumor growth for intra-lesional, systemic and multiple dose TAT., Results: Biodistribution studies showed similar pharmacokinetics for blood and brain, liver, kidneys, spleen, gut, heart, lungs and bone marrow, indicating that there was no retention of AIC. This is particularly important for brain (due to the presence of NG2+ cells) as the antibody 9.2.27 may reach NG2 positive cells. Tumor growth at 2-days post-inoculation was completely inhibited by TAT. The response to TAT was inversely proportional to tumor growth, i.e., a reduction in response was observed with increased tumor burden. A multiple dose regime was found to be more effective than single dose., Conclusions: TAT is effective for the treatment of micrometastatic melanoma, when the tumor is preangiogenic in the form of isolated cells or cell clusters. There is no evidence of retention of AIC in brain, kidneys and other vital organs.
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.